Other Pipelines

Pipeline	Modality	Target	Indication	Development Status
CU71	PO	Endothelial Dysfunction Blocker	Neurodegenerative Disease	Discovery
CU72	PO	Undisclosed	Idiopathic Pulmonary Fibrosis	Discovery
CU73	PO	Undisclosed	Thrombotic Diseases	Discovery
CU03	PO	Multi Target	Age-related Macular Degeneration	Completed Phase 2a clinical trial in Korea(2022.1Q)
CU104	PO	Indication expansion of CU06	Ulcerative Colitis	Completed Phase 1 clinical trial in the U.S
CU106	PO	Indication expansion of CU06	Immuno-Oncology Combination	Completed Phase 1 clinical trial in the U.S
MT-102	IV(mAb)	Tie2	Cancer	Discovery
MT-105	IV(TsAb)	Undisclosed	Inflammatory Bowel Disease	Discovery
MT-40X	IV	Undisclosed	Cancer	Discovery
CP01-R01	PO	Endothelial Dysfunction Blocker	Kidney Failure in Companion Animals	Phase 3 clinical trial in dogs ongoing (Korea)

MT-105

MT-105 - Irritable Bowel Disease

CU71

CU71 – Alzheimer's Disease

Therapeutic Mechanism of CU71 in Alzheimer's Disease

CU71, a BBB stabilizer, improves cognition bt restoring barrier function and reducting neuroinflammation in AD

Alzheimer's Disease: The Central Role of BBB and Neuroinflammation

Next-generation Neurovascular Stabilizer

An oral candidate targeting BBB dysfunction and neuroinflammation

Preclinical evidence

Reduced BBB leakage & neuroinflammation, improved memory, partial β-amyloid reduction

Mechanistic differentiation

Focuses on neurovascular stabilization, complementing anti-amyloid mAbs and potentially reducing ARIA risk

Broader applicability

Potential not only in AD but also in cerebral small vessel disease and vascular dementia

Commercial value

Oral, multi-target profile enhances accessibility and cost-effectiveness, providing distinct competitiveness vs. anti-amyloid therapies

CP01-R01

CP01-R01 – CKD in companion animals

Pivotal Ph 3 Trial in Canine with CKD to Evaluate CP01's Renal Efficacy

First oral endothelial stabilizer–based candidate for companion animal CKD therapy

Currently in Phase 3 clinical trial in dogs, with potential application in cats

Demonstrated renal protection by preserving endothelial function and reducing inflammation and fibrosis

Prevalence & Market Context

CKD affects up to 10% of elderly dogs
Prevalence reaches 35–60% in senior cats
Rising pet healthcare market highlights a strong unmet need for effective CKD therapies

Pipeline